Epysqli is used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia ...

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, ...

Teva Pharmaceuticals (TEVA) and Samsung Bioepis (SSNLF) announced the availability of EPYSQLI in the U.S. EPYSQLI is a biosimilar to Soliris ...

EPYSQLI is designed to treat gMG in adults who are anti-acetylcholine receptor antibody positive.

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR antibodies), ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The expanded application makes this the first ...

This CME program is designed to enhance neurologists' understanding and management of generalized myasthenia gravis (gMG ... surrounding neonatal Fc receptor (FcRn) inhibitors, including their ...

UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome ...

in adults with the rare autoimmune disorder generalised myasthenia gravis (gMG). The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody (MuSK) ...